Please assess the completion status of the following clinical trial:

Trial Title: Evaluation of the Non-inferiority of Cefoxitin Versus Imipenem/Cilastatin in the Treatment of Urinary Tract Infections Caused by ESBL-producing Escherichia Coli

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age ≥ 18 years~* Patient admitted to any medical or surgical department in the participating centre~* Documented urinary tract infection (other than cystitis), with or without bacteremia, caused by ESBL-producing E. coli susceptible in vitro to cefoxitin (minimal inhibition concentration \<= 8 mg/L and /or diameter ≥ 19 mm according to CA-SFM 2015) and resistant to fluoroquinolones and to association trimethoprim-sulfamethoxazole. An E. Coli urinary tract infection is defined according to SPILF 2014 Clarification by a leucocytury ≥ 104/mL and clinical significant limit at 103 UFC/ml, for the men or the women.~* Medical examination prior to inclusion~* Informed consent signed by the patient~* Patient affiliated to a French Sécurité Social regimen~Exclusion Criteria:~* Serious infection (severe sepsis, septic shock)~* Pregnant or breast-feeding women~* Chronic kidney failure (creatinine clearance \< 30 ml/min) and/or dialysis~* Hypersensibility to imipenem/cilastatine, to cefoxitine~* Hypersensibility to another antibiotics of cephalosporine class~* Hypersensibility to another antibiotics of carbapenem class~* Severe hypersensibility (ex :anaphylactic reaction, or serious cutaneous reaction) to all other antibiotics from beta lactamines family (ex : penicillins, monobactam)~* Treatment with ganciclovir and/or valproic acid~* Infection on the urinary cathether~* Empirical antibiotic therapy including an aminoglycoside~* Patient being treated with antibiotic(s) for another infection~* Patient participating to another interventional study~* Patient not compliant according to the investigator's opinion~* Patient under guardianship

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- cefoxitin (Type: EXPERIMENTAL): Cefoxitin 2 g administered intravenously three times a day. during 10 days for the treatment of pyelonephritis during 21 days for the treatment of prostatitis
- imipenem (Type: ACTIVE_COMPARATOR): Imimpenem 1 g administered intravenously three times a day. during 10 days for the treatment of pyelonephritis during 21 days for the treatment of prostatitis

Based on this trial design, predict the completion outcome and termination type (if applicable).